A sponsor launched a Phase II study in idiopathic pulmonary fibrosis, entering an already crowded field targeting the same small patient population. With a critical interim analysis tied to a major communication milestone, enrollment delays were not an option. Worldwide stepped in with a dynamic, adaptive enrollment strategy and ultimately surpassed targets while keeping the study on timeline and on budget.
Read our full case study to learn how Worldwide’s respiratory and interstitial lung disease team applied their expertise to surpass enrollment targets and meet the sponsor’s communication milestone.
